Professor John Hulleman

This group is dedicated to developing new therapies for retinal diseases such as age-related macular degeneration (AMD). They use a variety of approaches, including biochemistry, chemical biology, gene therapy, and drug discovery. They are using MSI resources to process and analyze batches of longitudinal imaging files and are receiving biostatistics assistance from MSI staff.